MYDCOMBI
Peakphenylephrine hydrochloride; tropicamide
NDAOPHTHALMICSPRAY, METERED
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
MYDCOMBI (phenylephrine hydrochloride; tropicamide) is tropicamide, the anticholinergic component of mydcombi, blocks the responses of the sphincter muscle of the iris, dilating the pupil (mydriasis). First approved in 2023.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDCOMBI is a fixed-dose combination ophthalmic spray containing phenylephrine hydrochloride (alpha-1 adrenergic agonist) and tropicamide (anticholinergic agent) approved in May 2023 for mydriasis (pupil dilation). The dual mechanism—phenylephrine contracts the iris dilator muscle while tropicamide blocks the sphincter muscle—provides rapid and sustained pupil dilation for diagnostic ophthalmologic procedures. This is a novel metered-spray formulation addressing an established clinical need in eye examination.
Growth5.2 years to LOE
Early-stage growth product with no direct competitors suggests opportunity for market expansion and team building in specialty eye care segments.
Mechanism of Action
Tropicamide, the anticholinergic component of MYDCOMBI, blocks the responses of the sphincter muscle of the iris, dilating the pupil (mydriasis). Phenylephrine hydrochloride, the alpha-1 adrenergic agonist component of MYDCOMBI, acts as a mydriatic agent by contracting the dilator muscle of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MYDCOMBI offers the opportunity to build a commercial franchise in an uncontested specialty ophthalmology market with strong patent protection through 2031. The early-stage growth lifecycle and zero competitor presence position this as a career-building platform for commercial professionals seeking category leadership and market-shaping influence.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.